» Articles » PMID: 32973780

Regulatory B Cells and Its Role in Central Nervous System Inflammatory Demyelinating Diseases

Overview
Journal Front Immunol
Date 2020 Sep 25
PMID 32973780
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Regulatory B (Breg) cells represent a population of suppressor B cells that participate in immunomodulatory processes and inhibition of excessive inflammation. The regulatory function of Breg cells have been demonstrated in mice and human with inflammatory diseases, cancer, after transplantation, and particularly in autoinflammatory disorders. In order to suppress inflammation, Breg cells produce anti-inflammatory mediators, induce death ligand-mediated apoptosis, and regulate many kinds of immune cells such as suppressing the proliferation and differentiation of effector T cell and increasing the number of regulatory T cells. Central nervous system Inflammatory demyelinating diseases (CNS IDDs) are a heterogeneous group of disorders, which occur against the background of an acute or chronic inflammatory process. With the advent of monoclonal antibodies directed against B cells, breakthroughs have been made in the treatment of CNS IDDs. Therefore, the number and function of B cells in IDDs have attracted attention. Meanwhile, increasing number of studies have confirmed that Breg cells play a role in alleviating autoimmune diseases, and treatment with Breg cells has also been proposed as a new therapeutic direction. In this review, we focus on the understanding of the development and function of Breg cells and on the diversification of Breg cells in CNS IDDs.

Citing Articles

Inherent immunity and adaptive immunity: Mechanism and role in AECOPD.

Wu L, Zhang E, Tu Y, Chen Y, Wang C, Ren Y Innate Immun. 2025; 31:17534259251322612.

PMID: 40017227 PMC: 11869301. DOI: 10.1177/17534259251322612.


Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis.

Chen H Front Pharmacol. 2025; 15:1521726.

PMID: 39917326 PMC: 11799251. DOI: 10.3389/fphar.2024.1521726.


Unraveling the Role of Endothelial Dysfunction in Osteonecrosis of the Femoral Head: A Pathway to New Therapies.

Shao W, Wang P, Lv X, Wang B, Gong S, Feng Y Biomedicines. 2024; 12(3).

PMID: 38540277 PMC: 10967783. DOI: 10.3390/biomedicines12030664.


Osteoimmunology: The Crosstalk between T Cells, B Cells, and Osteoclasts in Rheumatoid Arthritis.

Yang M, Zhu L Int J Mol Sci. 2024; 25(5).

PMID: 38473934 PMC: 10931770. DOI: 10.3390/ijms25052688.


An engineered Fc fusion protein that targets antigen-specific T cells and autoantibodies mitigates autoimmune disease.

Janakiraman M, Leliavski A, Varadarajulu J, Jenne D, Krishnamoorthy G J Neuroinflammation. 2023; 20(1):291.

PMID: 38057803 PMC: 10702099. DOI: 10.1186/s12974-023-02974-9.


References
1.
Benedek G, Zhang J, Nguyen H, Kent G, Seifert H, Vandenbark A . Novel feedback loop between M2 macrophages/microglia and regulatory B cells in estrogen-protected EAE mice. J Neuroimmunol. 2017; 305:59-67. PMC: 5387865. DOI: 10.1016/j.jneuroim.2016.12.018. View

2.
Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M . Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014; 82(15):1302-6. PMC: 4001188. DOI: 10.1212/WNL.0000000000000317. View

3.
Rojas O, Probstel A, Porfilio E, Wang A, Charabati M, Sun T . Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10. Cell. 2019; 176(3):610-624.e18. PMC: 6903689. DOI: 10.1016/j.cell.2018.11.035. View

4.
Milo R, Miller A . Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev. 2014; 13(4-5):518-24. DOI: 10.1016/j.autrev.2014.01.012. View

5.
Rincon-Arevalo H, Sanchez-Parra C, Castano D, Yassin L, Vasquez G . Regulatory B Cells and Mechanisms. Int Rev Immunol. 2015; 35(2):156-76. DOI: 10.3109/08830185.2015.1015719. View